Welch & Forbes’s Celgene Corp CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-13,750
Closed -$1.37M 361
2019
Q3
$1.37M Sell
13,750
-6,857
-33% -$652K 0.03% 188
2019
Q2
$1.91M Sell
20,607
-11,991
-37% -$1.14M 0.05% 165
2019
Q1
$3.08M Sell
32,598
-94,687
-74% -$8.28M 0.08% 146
2018
Q4
$8.16M Sell
127,285
-70,595
-36% -$5.21M 0.23% 100
2018
Q3
$17.7M Sell
197,880
-3,952
-2% -$349K 0.42% 72
2018
Q2
$16M Sell
201,832
-90,512
-31% -$7.52M 0.41% 73
2018
Q1
$26.1M Buy
292,344
+17,468
+6% +$1.68M 0.67% 51
2017
Q4
$28.7M Buy
274,876
+10,277
+4% +$1.16M 0.77% 43
2017
Q3
$38.6M Buy
264,599
+6,126
+2% +$834K 1.02% 33
2017
Q2
$33.6M Buy
258,473
+8,145
+3% +$998K 0.94% 33
2017
Q1
$31.1M Buy
250,328
+8,506
+4% +$1.02M 0.89% 35
2016
Q4
$28M Buy
241,822
+13,584
+6% +$1.51M 0.84% 38
2016
Q3
$23.9M Sell
228,238
-2,487
-1% -$269K 0.83% 40
2016
Q2
$22.8M Buy
230,725
+6,704
+3% +$693K 0.69% 49
2016
Q1
$22.4M Buy
224,021
+19,794
+10% +$2.04M 0.7% 48
2015
Q4
$24.5M Buy
204,227
+3,986
+2% +$461K 0.78% 42
2015
Q3
$21.7M Buy
200,241
+14,444
+8% +$1.79M 0.72% 44
2015
Q2
$21.5M Buy
185,797
+1,131
+0.6% +$129K 0.67% 49
2015
Q1
$21.3M Buy
184,666
+6,018
+3% +$719K 0.64% 55
2014
Q4
$20M Buy
178,648
+7,191
+4% +$758K 0.59% 61
2014
Q3
$16.3M Buy
171,457
+11,588
+7% +$1.05M 0.5% 71
2014
Q2
$13.7M Buy
159,869
+14,307
+10% +$1.09M 0.43% 72
2014
Q1
$10.2M Buy
145,562
+91,498
+169% +$7.25M 0.32% 87
2013
Q4
$4.57M Buy
54,064
+31,656
+141% +$2.5M 0.14% 124
2013
Q3
$1.73M Buy
22,408
+17,128
+324% +$1.2M 0.06% 168
2013
Q2
$309K Buy
+5,280
New +$318K 0.01% 268

Other funds holding CELG

Welch & Forbes's CELG Position: Q4 2019 in Review

Welch & Forbes sold out of Celgene Corp (CELG) in Q4 2019, closing a stake of 13,750 shares — an estimated $1.37M sold.

Welch & Forbes first reported a position in CELG in Q2 2013 and held it in 26 quarters. The position peaked at $38.6M in Q3 2017. 4 funds tracked by Wall St. Rank hold CELG as of Q4 2019.

  • Welch & Forbes reported no remaining Celgene Corp position as of Q4 2019 after selling out during the quarter.
  • Welch & Forbes sold 13,750 Celgene Corp shares in Q4 2019, an estimated $1.37M.
  • Welch & Forbes first reported a position in Celgene Corp in Q2 2013 and held it in 26 quarters.
  • Welch & Forbes's Celgene Corp position peaked at $38.6M in Q3 2017.
  • 4 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2019.

Based on Welch & Forbes's 13F filing for Q4 2019, filed 17 Jan 2020.